Edwards Lifesciences (LTS:0REN) Interest Expense: CHF-16 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0REN Edwards Lifesciences Corp LTS:0REN
97 GF Score
Price CHF77.56
GF Value CHF80.65
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Interest Expense?

Edwards Lifesciences LTS:0REN 97 Interest Expense is CHF-16 Mil as of Mar. 2026. GuruFocus rates LTS:0REN with a GF Score™ of 97/100 and a GF Value™ of CHF80.65. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Edwards Lifesciences's interest expense for the three months ended in Mar. 2026 was CHF 0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-16 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Edwards Lifesciences's Operating Income for the three months ended in Mar. 2026 was CHF 405 Mil. Edwards Lifesciences's Interest Expense for the three months ended in Mar. 2026 was CHF 0 Mil. GuruFocus does not calculate Edwards Lifesciences's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Edwards Lifesciences  (LTS:0REN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Edwards Lifesciences's Interest Expense for the three months ended in Mar. 2026 was CHF0 Mil. Its Operating Income for the three months ended in Mar. 2026 was CHF405 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was CHF534 Mil.

Edwards Lifesciences's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Edwards Lifesciences's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Edwards Lifesciences Corp has enough cash to cover all of its debt. Its financial situation is stable.

Edwards Lifesciences Interest Expense Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Interest Expense Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.95 -17.89 -15.22 -17.65 -16.26

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -16.26 0.00
LTS:0REN
97GF Score
Edwards Lifesciences Corp LTS:0REN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of CHF-16 Mil mean?
Edwards Lifesciences (LTS:0REN) has a Interest Expense of CHF-16 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Interest Expense too high?
Edwards Lifesciences' current Interest Expense is CHF-16 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Interest Expense compare to BSX and GEHC?
Edwards Lifesciences' Interest Expense of CHF-16 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Interest Expense is CHF-16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (LTS:0REN) has a current Interest Expense of CHF-16 Mil. The stock's GF Value™ is CHF80.65, compared to a current price of CHF77.56 — trading 3.8% below its estimated fair value. The current Interest Expense is CHF-16 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Edwards Lifesciences (LTS:0REN), the current Interest Expense is CHF-16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (LTS:0REN) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF77.56 is trading 3.8% below its estimated GF Value™ of CHF80.65.

Key valuation signals for LTS:0REN:

  • Interest Expense: CHF-16 Mil
  • GF Value™: CHF80.65 vs. price of CHF77.56 (3.8% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the LTS:0REN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for LTS:0REN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF77.56
Price
CHF80.65
GF Value